Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives $7.50 Average PT from Analysts

Pyxis Oncology, Inc. (NASDAQ:PYXS) has received a consensus rating of “Moderate Buy” from the ten ratings firms that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and eight have given a buy recommendation to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $7.50.

Several equities analysts have commented on the stock. Leerink Partners lowered their target price on shares of Pyxis Oncology from $9.00 to $7.00 and set an “outperform” rating on the stock in a research report on Thursday, July 2nd. Weiss Ratings cut Pyxis Oncology from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, June 30th. Wells Fargo & Company started coverage on Pyxis Oncology in a research note on Monday, August 3rd. They set an “overweight” rating and a $12.00 price target for the company. Wedbush began coverage on Pyxis Oncology in a report on Tuesday, May 5th. They set an “outperform” rating and a $6.00 price objective on the stock. Finally, Wall Street Zen downgraded Pyxis Oncology from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th.

Pyxis Oncology Stock Up 0.3%

PYXS stock opened at $3.02 on Friday. The firm has a 50 day moving average of $2.58 and a two-hundred day moving average of $1.98. Pyxis Oncology has a 12 month low of $1.03 and a 12 month high of $5.55. The company has a market capitalization of $191.32 million, a price-to-earnings ratio of -2.14 and a beta of 1.31.

Pyxis Oncology (NASDAQ:PYXS) last released its quarterly earnings results on Thursday, August 13th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.05). On average, research analysts expect that Pyxis Oncology will post -1.26 EPS for the current fiscal year.

Hedge Funds Weigh In On Pyxis Oncology

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Laurion Capital Management LP raised its position in shares of Pyxis Oncology by 32.3% in the fourth quarter. Laurion Capital Management LP now owns 4,796,479 shares of the company’s stock valued at $5,516,000 after purchasing an additional 1,170,505 shares during the period. Atle Fund Management AB bought a new stake in shares of Pyxis Oncology during the 4th quarter worth $710,000. Bank of America Corp DE grew its stake in Pyxis Oncology by 2,690.9% in the 3rd quarter. Bank of America Corp DE now owns 615,922 shares of the company’s stock valued at $1,367,000 after buying an additional 593,853 shares during the last quarter. Longaeva Partners L.P. acquired a new position in Pyxis Oncology in the 3rd quarter valued at $1,117,000. Finally, Jane Street Group LLC raised its holdings in Pyxis Oncology by 158.8% in the 4th quarter. Jane Street Group LLC now owns 786,010 shares of the company’s stock worth $904,000 after acquiring an additional 482,310 shares during the period. Institutional investors and hedge funds own 39.07% of the company’s stock.

About Pyxis Oncology

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.